The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications - PubMed (original) (raw)

Review

The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications

Qingguang Jiang et al. CNS Drugs. 2008.

Abstract

Alzheimer's disease is a complex neurodegenerative disorder, with aging, genetic and environmental factors contributing to its development and progression. The complexity of Alzheimer's disease presents substantial challenges for the development of new therapeutic agents. Alzheimer's disease is typified by pathological depositions of beta-amyloid peptides and neurofibrillary tangles within the diseased brain. It has also been demonstrated to be associated with a significant microglia-mediated inflammatory component, dysregulated lipid homeostasis and regional deficits in glucose metabolism within the brain. The peroxisome proliferator-activated receptor-gamma (PPARgamma) is a prototypical ligand-activated nuclear receptor that coordinates lipid, glucose and energy metabolism, and is found in elevated levels in the brains of individuals with Alzheimer's disease. A recently appreciated physiological function of this type of receptor is its ability to modulate inflammatory responses. In animal models of Alzheimer's disease, PPARgamma agonist treatment results in the reduction of amyloid plaque burden, reduced inflammation and reversal of disease-related behavioural impairment. In a recent phase II clinical trial, the use of the PPARgamma agonist rosiglitazone was associated with improved cognition and memory in patients with mild to moderate Alzheimer's disease. Thus, PPARgamma may act to modulate multiple pathophysiological mechanisms that contribute to Alzheimer's disease, and represents an attractive therapeutic target for the treatment of the disease.

PubMed Disclaimer

Similar articles

• PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
  Landreth G, Jiang Q, Mandrekar S, Heneka M. Landreth G, et al. Neurotherapeutics. 2008 Jul;5(3):481-9. doi: 10.1016/j.nurt.2008.05.003. Neurotherapeutics. 2008. PMID: 18625459 Free PMC article. Review.
• Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update.
  Khan MA, Alam Q, Haque A, Ashafaq M, Khan MJ, Ashraf GM, Ahmad M. Khan MA, et al. Curr Neuropharmacol. 2019;17(3):232-246. doi: 10.2174/1570159X16666180828100002. Curr Neuropharmacol. 2019. PMID: 30152284 Free PMC article. Review.
• Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease.
  Landreth G. Landreth G. Curr Alzheimer Res. 2007 Apr;4(2):159-64. doi: 10.2174/156720507780362092. Curr Alzheimer Res. 2007. PMID: 17430241 Review.
• The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.
  Watson GS, Craft S. Watson GS, et al. CNS Drugs. 2003;17(1):27-45. doi: 10.2165/00023210-200317010-00003. CNS Drugs. 2003. PMID: 12467491 Review.
• [Alzheimer's disease].
  Hanyu H, Sato T. Hanyu H, et al. Nihon Rinsho. 2010 Feb;68(2):330-4. Nihon Rinsho. 2010. PMID: 20158105 Review. Japanese.

Cited by

• Chronic caloric restriction attenuates a loss of sulfatide content in PGC-1α-/- mouse cortex: a potential lipidomic role of PGC-1α in neurodegeneration.
  Kiebish MA, Young DM, Lehman JJ, Han X. Kiebish MA, et al. J Lipid Res. 2012 Feb;53(2):273-81. doi: 10.1194/jlr.M020628. Epub 2011 Nov 23. J Lipid Res. 2012. PMID: 22114039 Free PMC article.
• Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action.
  Ożarowski M, Karpiński TM, Zielińska A, Souto EB, Wielgus K. Ożarowski M, et al. Int J Mol Sci. 2021 Apr 21;22(9):4294. doi: 10.3390/ijms22094294. Int J Mol Sci. 2021. PMID: 33919010 Free PMC article. Review.
• Application of Micro-Western Array for Identifying Different Serum Protein Expression Profile among Healthy Control, Alzheimer's Disease Patients and Patients' Adult Children.
  Huo C, Chen MH, Hour TC, Huang LC, Fong YO, Kuo YY, Yang YH, Chuu CP. Huo C, et al. Brain Sci. 2022 Aug 26;12(9):1134. doi: 10.3390/brainsci12091134. Brain Sci. 2022. PMID: 36138870 Free PMC article.
• The Unveiling of Therapeutic Targets for Alzheimer's Disease: An Integrative Review.
  Madar P, Nagalapur P, Chaudhari S, Sharma D, Koparde A, Buchade R, Kshirsagar S, Uttekar P, Jadhav S, Chaudhari P. Madar P, et al. Curr Top Med Chem. 2024;24(10):850-868. doi: 10.2174/0115680266282492240220101049. Curr Top Med Chem. 2024. PMID: 38424435 Review.
• A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease.
  Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM. Roses AD, et al. Pharmacogenomics J. 2010 Oct;10(5):375-84. doi: 10.1038/tpj.2009.69. Epub 2009 Dec 22. Pharmacogenomics J. 2010. PMID: 20029386 Free PMC article.

References

1. 1. Exp Neurol. 2004 Nov;190(1):245-53 - PubMed
2. 1. Gerontology. 1997;43(1-2):143-9 - PubMed
3. 1. Am J Med. 2004 Jul 15;117(2):109-17 - PubMed
4. 1. Nature. 2000 May 25;405(6785):421-4 - PubMed
5. 1. J Neurosci. 2001 Apr 15;21(8):2561-70 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information